Literature DB >> 29709729

Smoking and FGFR2 rs2981582 variant independently modulate male breast cancer survival: A population-based study in Tuscany, Italy.

Ines Zanna1, Valentina Silvestri2, Domenico Palli3, Alessandro Magrini1, Piera Rizzolo2, Calogero Saieva1, Veronica Zelli2, Benedetta Bendinelli1, Vania Vezzosi4, Virginia Valentini2, Simonetta Bianchi4, Laura Ottini2, Giovanna Masala1.   

Abstract

AIM: Male breast cancer (MBC) is a rare disease and recommendations for its clinical management are often extrapolated from those for female breast cancer, even if breast cancer (BC) has different characteristics in the two sexes. The purpose of this study was to assess the influence of several individual characteristics including clinico-pathological, lifestyle and genetic factors on overall survival (OS) of a relatively large and well characterized population-based series of 166 MBCs enrolled in Tuscany.
METHODS: We genotyped MBC cases at BRCA1/2 genes and at 9 candidate BC susceptibility SNPs. Kaplan-Meier method and multivariate Cox regression, adjusted for several individual characteristics were used. To reduce a possible selection bias related to the interval between diagnosis and enrolment of MBC cases into the study, we used the date of blood donation as the date of the start of observation for survival analysis.
RESULTS: Only smoking habits had a significant effect on OS at 10 years (for current smokers, HR: 3.34; 95% CI 1.45-7.68; p = 0.004), while lymph node status fell short of reaching statistical significance (for pN positive, HR: 2.07; 95% CI 0.93-4.55; p = 0.07). In the same multivariate analysis we found a significantly higher OS in cases with FGFR2 rs2981582 variant in the dominant transmission model (HR: 0.29; 95% CI: 0.13-0.62; p = 0.028). A sensitivity analysis with left truncation showed similar results.
CONCLUSIONS: Our results may contribute to shed light on factors influencing MBC survival suggesting an important role for cigarette smoking and FGFR2 rs2981582 variant, and provide clues for better patient management.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Cigarette smoking; FGFR2; Male; Population-based study; Survival

Mesh:

Substances:

Year:  2018        PMID: 29709729     DOI: 10.1016/j.breast.2018.04.017

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  2 in total

1.  Ribociclib Plus Letrozole in Italian Male Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Case Studies of Phase 3b CompLEEment-1 Trial.

Authors:  Roberta Caputo; Alessandra Fabi; Emanuela Romagnoli; Editta Baldini; Donatella Grasso; Nicola Fenderico; Andrea Michelotti
Journal:  Breast Cancer (Dove Med Press)       Date:  2022-10-18

Review 2.  Analysis of the Clinical Advancements for BRCA-Related Malignancies Highlights the Lack of Treatment Evidence for BRCA-Positive Male Breast Cancer.

Authors:  Dylan P McClurg; Gordan Urquhart; Trevor McGoldrick; Subarnarekha Chatterji; Zosia Miedzybrodzka; Valerie Speirs; Beatrix Elsberger
Journal:  Cancers (Basel)       Date:  2022-06-28       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.